Cargando…

Use of Glycolysis‐Enhancing Drugs and Risk of Parkinson's Disease

BACKGROUND: Terazosin (TZ) and closely related α1‐adrenergic receptor antagonists (doxazosin [DZ] and alfuzosin [AZ]) enhance glycolysis and reduce neurodegeneration in animal models. Observational evidence in humans from several databases supports this finding; however, a recent study has suggested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simmering, Jacob E., Welsh, Michael J., Schultz, Jordan, Narayanan, Nandakumar S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669185/ https://www.ncbi.nlm.nih.gov/pubmed/36054705 http://dx.doi.org/10.1002/mds.29184

Ejemplares similares

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease
por: Simmering, Jacob E., et al.
Publicado: (2021)

Glycolysis-enhancing α(1)-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease
por: Weber, Matthew A., et al.
Publicado: (2023)

61 Detecting Parkinson’s Disease Using Computer Vision
por: Simmering, Jacob, et al.
Publicado: (2023)

Salience network and cognitive impairment in Parkinson’s disease
por: Yeager, Brooke E, et al.
Publicado: (2023)

Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models
por: Hong, Chien Tai, et al.
Publicado: (2016)

Executive dysfunction in Parkinson’s disease and timing deficits
por: Parker, Krystal L., et al.
Publicado: (2013)

Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?
por: Harris, Shana, et al.
Publicado: (2023)

Loss of UCHL1 rescues the defects related to Parkinson’s disease by suppressing glycolysis
por: Ham, Su Jin, et al.
Publicado: (2021)

Parkinson’s Disease Dementia and Dementia with Lewy Bodies Have Similar Neuropsychological Profiles
por: Aldridge, Georgina M., et al.
Publicado: (2018)

Weather-Dependent Risk for Legionnaires’ Disease, United States
por: Simmering, Jacob E., et al.
Publicado: (2017)

The Association Between Technology Use and Health Status in a Chronic Obstructive Pulmonary Disease Cohort: Multi-Method Study
por: Witry, Matthew, et al.
Publicado: (2018)

Optogenetic approaches to evaluate striatal function in animal models of Parkinson disease
por: Parker, Krystal L., et al.
Publicado: (2016)

Mangiferin Accelerates Glycolysis and Enhances Mitochondrial Bioenergetics
por: Liu, Zhongbo, et al.
Publicado: (2018)

Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells
por: Smith, Amy M., et al.
Publicado: (2018)

The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing
por: Tesori, Valentina, et al.
Publicado: (2015)

Using Search Volume for Surveillance of Medication Prescribing
por: Simmering, Jacob E., et al.
Publicado: (2013)

Resting-state EEG measures cognitive impairment in Parkinson’s disease
por: Anjum, Md Fahim, et al.
Publicado: (2023)

Peripheral Glycolysis in Neurodegenerative Diseases
por: Bell, Simon M., et al.
Publicado: (2020)

Linear Predictive Approaches Separate Field Potentials in Animal Model of Parkinson's Disease
por: Anjum, Md Fahim, et al.
Publicado: (2020)

Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease
por: Singh, Arun, et al.
Publicado: (2021)

The phasor-FLIM fingerprints reveal shifts from OXPHOS to enhanced glycolysis in Huntington Disease
por: Sameni, Sara, et al.
Publicado: (2016)

Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis
por: Liu, Ru-Tao, et al.
Publicado: (2018)

A pilot study of machine learning of resting-state EEG and depression in Parkinson’s disease
por: Espinoza, Arturo I., et al.
Publicado: (2022)

Use of non-steroidal anti-inflammatory drugs and risk of Parkinson’s disease: nested case-control study
por: Driver, Jane A, et al.
Publicado: (2011)

Improving estimation of Parkinson’s disease risk—the enhanced PREDICT-PD algorithm
por: Bestwick, Jonathan P., et al.
Publicado: (2021)

Brain aerobic glycolysis and resilience in Alzheimer disease
por: Goyal, Manu S., et al.
Publicado: (2023)

2-Deoxyglucose, an Inhibitor of Glycolysis, Enhances the Oncolytic Effect of Coxsackievirus
por: Vorobyev, Pavel O., et al.
Publicado: (2022)

HSP90 facilitates stemness and enhances glycolysis in glioma cells
por: Kang, Xun, et al.
Publicado: (2022)

Drug treatment of Parkinson's disease
por: Korczyn, Amos D.
Publicado: (2004)

Advances in Parkinson’s Disease Drugs
por: Di Stefano, Antonio, et al.
Publicado: (2021)

Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer
por: Cargill, Kasey R., et al.
Publicado: (2021)

Glycolysis Is an Intrinsic Factor for Optimal Replication of a Norovirus
por: Passalacqua, Karla D., et al.
Publicado: (2019)

Natural products target glycolysis in liver disease
por: Li, Shenghao, et al.
Publicado: (2023)

Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
por: Akins, Nicholas S., et al.
Publicado: (2018)

Glycolysis-induced drug resistance in tumors—A response to danger signals?
por: Marcucci, Fabrizio, et al.
Publicado: (2021)

G-protein coupled receptor kinases in inflammation and disease
por: Packiriswamy, Nandakumar, et al.
Publicado: (2015)

PFKM inhibits doxorubicin-induced cardiotoxicity by enhancing oxidative phosphorylation and glycolysis
por: Zhou, Min, et al.
Publicado: (2022)

m(6)A-dependent glycolysis enhances colorectal cancer progression
por: Shen, Chaoqin, et al.
Publicado: (2020)

GLUT-1 Enhances Glycolysis, Oxidative Stress, and Fibroblast Proliferation in Keloid
por: Lu, Ying-Yi, et al.
Publicado: (2021)

Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
por: Han, Sola, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8o0t1scmu7agjmnemvs5qst0lg